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Abstract
Background: Use of bridging anticoagulation increases a patient's bleeding risk with-
out clear evidence of thrombotic prevention among warfarin-treated patients with 
atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin-
treated patients with venous thromboembolism (VTE) has not been studied.
Methods: We identified warfarin-treated patients with VTE who temporarily stopped 
warfarin for a surgical procedure between 2010 and 2018 at six health systems. 
Using the 2012 American College of Chest Physicians guideline, we assessed use 
of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent 
VTE risk and 30-day outcomes (bleeding, thromboembolism, emergency department 
visit) were each assessed using logistic regression adjusted for multiple procedures 
per patient.
Results: During the study period, 789 warfarin-treated patients with VTE underwent 
1529 procedures (median, 2; interquartile range, 1-4). Unadjusted use of bridging an-
ticoagulation was more common in patients at high risk for VTE recurrence (99/171, 
57.9%) than for patients at moderate (515/1078, 47.8%) or low risk of recurrence 
(134/280, 47.86%). Bridging anticoagulation use was higher in high-risk patients com-
pared with low- or moderate-risk patients in both unadjusted (P = .013) and patient-
level cluster-adjusted analyses (P = .031). Adherence to American College of Chest 
Physicians guidelines in high- and low-risk patients did not change during the study 
period (odds ratio, 0.98 per year; 95% confidence interval, 0.91-1.05). Adverse events 
were rare and not statistically different between the two treatment groups.
Conclusions: Bridging anticoagulation was commonly overused among low-risk 
patients and underused among high-risk patients treated with warfarin for VTE. 
Adverse events were rare and not different between the two treatment groups.
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1  | INTRODUC TION
Vitamin K antagonists, such as warfarin, remain a leading treatment 
option worldwide for patients with venous thromboembolism (VTE). 
Although some patients require only short 3- or 6-month courses 
of treatment, an increasing proportion of patients with VTE are 
treated with oral anticoagulant medications indefinitely to prevent 
recurrence.1,2 These patients frequently require temporary inter-
ruption of anticoagulation therapy for elective invasive or surgical 
procedures, such as colonoscopy and orthopedic surgery. Given the 
relatively long period while warfarin's anticoagulant effect wears off 
before surgery or builds back up after surgery, many clinicians have 
historically used shorter acting “bridging” anticoagulants, like low 
molecular weight heparins (LMWH), to help reduce the risk of VTE 
recurrence. However, the efficacy of bridging anticoagulation has 
been questioned in a recently published analyses of patients with 
VTE.3,4 However, both of these analysis largely included patients 
treated up to a decade ago. A contemporary, multicenter analysis of 
bridging LMWH use in patients with VTE has not been performed. 
This is of particular importance given recent efforts to reduce the 
overall use of bridging anticoagulation among patients with atrial 
fibrillation, based largely on the BRIDGE trial published in 2015.5
We used a multicenter collaborative of anticoagulation clinics 
to explore the use of bridging anticoagulation among patients with 
VTE treated with warfarin. We assessed the association between 
VTE risk and use of bridging anticoagulation, based on the 2012 
American College of Chest Physicians (ACCP) guidelines. We also 




We used the Michigan Anticoagulation Quality Improvement Initiative 
(MAQI2) registry to explore the use of bridging anticoagulation (pri-
marily with LMWH) among chronic warfarin-treated patients with 
VTE between July 2010 and December 2018. This six-center regis-
try of warfarin-treated patients managed in anticoagulation clinics 
across the state of Michigan is sponsored by Blue Cross-Blue Shield/
Blue Care Network of Michigan.6 Patients newly initiating warfarin at 
one of the participating health care centers and managed longitudi-
nally in the anticoagulation clinic are randomly selected to be enrolled 
and followed in the MAQI2 registry through retrospective data collec-
tion. Enrollment in the registry has no impact on clinical care (including 
periprocedural), which is directed by the individual patient's providers. 
No MAQI2-led quality initiatives targeted at bridging anticoagulation 
use were under way during the study period. Patients are followed 
until warfarin therapy is discontinued or the patient is no longer fol-
lowed by the anticoagulation clinic. Trained abstractors perform data 
abstraction manually using standardized data forms with prespecified 
data dictionaries. Data abstractors examined the medical record for 
adverse events resulting in care at their particular health center as well 
as any that was reported to the anticoagulation clinic but may have 
occurred at an outside hospital or clinic. Random audits are performed 
by the MAQI2 coordinating center to ensure data abstraction accuracy. 
Institutional review board approval was obtained at each participating 
site and at the coordinating center (University of Michigan).
2.2 | Patient selection
To be included in the study, patients had to be receiving warfarin 
therapy, followed by one of the six participating health centers, and 
have VTE as their only indication for warfarin therapy. Patients with 
multiple indications (eg, atrial fibrillation and VTE) for anticoagula-
tion were excluded. Patients were required to have at least 30 days 
of continuous warfarin use both before and immediately following a 
temporary interruption for a surgical or other invasive procedure (eg 
colonoscopy) and had a temporary interruption of warfarin therapy 
between July 2010 and December 2018.
2.3 | Outcomes
The primary outcome was the use of bridging anticoagulation, 
defined as the use of therapeutic doses of intravenous unfrac-
tionated heparin, subcutaneous LMWH, or subcutaneous fon-
daparinux at any time during the 5 days before and/or following 
surgery or procedure (subsequently referred to as “bridging anti-
coagulation”). Prophylactic doses of anticoagulants were not in-
cluded in the outcome measure. Adverse events within 30 days 
of the index procedure were manually chart abstracted as any 
bleeding, major bleeding as defined by the International Society 
Essentials
• Between 2010 and 2018, use of bridging anticoagula-
tion was more common for patients at high thromboem-
bolic risk than low or moderate risk.
• There was no meaningful change in the use of guideline-
concordant bridging anticoagulation during the study 
period.
K E Y W O R D S
anticoagulation, heparin, low-molecular-weight, perioperative, venous thromboembolism, 
warfarin
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on Thrombosis and Haemostasis, any emergency department visit, 
stroke, or recurrent VTE.7
Our primary analysis compared the rate of bridging anticoagula-
tion based on the 2012 ACCP guideline for perioperative manage-
ment.8 Specifically, patients at high risk for recurrent VTE were those 
with their index VTE event <3 months before their procedure date or 
patients with the antiphospholipid antibody syndrome. Patients at 
moderate risk for recurrent VTE were those whose index VTE event 
was 3 to 12 months before their procedure date, had a history of 
cancer, had a history of recurrent VTE, or had a known thrombo-
philia other than antiphospholipid antibody syndrome. Patients with 
an index VTE event >12 months before the procedure and without 
any of the previously mentioned comorbidities were considered low 
risk for recurrent VTE. According to the ACCP guidelines, bridging 
anticoagulation is recommended for patients at high risk for recur-
rent VTE and not recommended for patients at low risk for recurrent 
VTE (grade 2C). Because patients with moderate risk of recurrent 
VTE do not have a guideline-recommended strategy, analysis of 
guideline-congruent bridging use focused only on patient with low 
or high risk of recurrent VTE.
2.4 | Statistical analysis
A linear regression analysis was performed to assess for changes 
in bridging anticoagulation use over time. This trend analysis was 
performed for all patients as well as individually for low- and high-
risk patients. Association between level of recurrent VTE risk 
and use of bridging anticoagulation was first assessed using chi-
squared analysis. We then performed logistic regression adjusting 
for multiple procedures per patient. Next, we assessed for guide-
line compliance in the use of bridging anticoagulation. Another 
logistic regression model was developed to predict guideline con-
gruence over time, adjusted for multiple procedures per patient. In 
sensitivity analysis, we compared use of bridging anticoagulation 
and guideline congruence for patients with deep vein thrombo-
sis (DVT) only separately from patients with pulmonary embolism 
with or without DVT.
To assess for rates of adverse events, we examined for any re-
ported bleeding or thromboembolic event as well as any emergency 
department visit that occurred within 30 days following the proce-
dure and was documented in the medical record. Differences in ad-
verse event rates were compared using chi-squared analyses.
Statistical significance was set at an alpha of 0.05. Statistical 
analyses were performed using Stata version 15.1 (College Station, 
TX).
3  | RESULTS
Between July 2015 and December 2018, 791 warfarin-treated pa-
tients with VTE experienced 1529 temporary interruptions for sur-
gical or invasive procedures (median, 2.0 procedures per patient; 
interquartile range, 1-4). Patient demographics and comorbidities 
are summarized in Table 1 and show important differences in age 
(66.5 vs 61.4 years), male (52.0% vs 46.5%), prior VTE (38.0% vs 
44.4%), provoked VTE (31.7% vs 19.5%), and number of comorbidi-
ties between patients who did not and those who did receive bridg-
ing anticoagulation. Most patients were on warfarin therapy for 
more than 1 year at the time of their procedural interruption (mean, 
997 [standard deviation, 1302] days). Bridging was used in 748/1529 
(48.9%) of all procedures. Procedure type by bridging anticoagula-
tion use is shown in the Appendix S1.
3.1 | Bridging anticoagulation by VTE risk
Bridging anticoagulation was used more commonly in patients 
at high risk for recurrent VTE than in patients at low or moder-
ate risk (57.9% vs 47.8%, P = .013; Table 2). After adjusting for 
multiple procedures per patient, bridging anticoagulation was 
more common among high-risk patient (odds ratio, 1.50; 95% 
confidence interval, 1.04-2.17; P = .031). Use of bridging anti-
coagulation was numerically, but not statistically significantly, 
higher among patients VTE in the past 90 days (88/158, 55.7%) 
compared with 90 to 364 days (198/420, 47.1%) or ≥365 days 
(462/951, 48.6%; P = .234). Use of bridging anticoagulation was 
higher among patients with antiphospholipid antibody syndrome 
(12/14, 85.7%) compared with those without (736/1520, 48.4%; 
P = .006). Bridging anticoagulation use by various VTE risk ele-
ments are shown in the Appendix S1.
Among patients with either low or high risk for recurrent VTE, 
guideline-congruent use of bridging anticoagulation ranges from 
48.1% to 68.2% of patients between 2010 and 2018 (Ptrend = .597; 
Figure 1). In sensitivity analysis, use of bridging anticoagulation was 
more common among high-risk patients with DVT only (57.7% vs 
44.4%, P = .005) but not among patients with PE (56.5% vs 51.5%, 
P = .456). There was no change in guideline-congruent bridging anti-
coagulation use during the study period for both low- (Ptrend = .766) 
and high-risk patients (Ptrend = .760; Appendix S1).
3.2 | Adverse events
Rates of 30-day adverse events were low among all patients 
(Table 2). Any bleeding occurred in fewer than 3% of patients in both 
the bridging and nonbridging anticoagulation groups, and major 
bleeding rates, stroke rates, and recurrent VTE rates were similarly 
low. Overall, fewer than 4% of each cohort required an emergency 
department visit within 30 days following their procedure.
4  | DISCUSSION
Our study demonstrates that contemporary use of bridging an-
ticoagulation among warfarin-treated patients with VTE is often 
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not congruent with ACCP guideline recommendations and has not 
changed significantly over the 9-year study period. Specifically, 
there is significant overuse of bridging anticoagulation among pa-
tients at low risk for recurrent VTE. Patients at high risk for recurrent 
VTE are frequently not receiving bridging anticoagulation. Overall, 
rates of adverse events are low in both patients who did and did not 
receive bridging anticoagulation.
Overuse of bridging anticoagulation among patients at low risk 
for recurrent VTE is of particular concern. There have been nu-
merous publications suggesting a lack of significant benefit with 
bridging therapy for these low-risk patients. First, Clark and col-
leagues reported no significant reduction in VTE recurrence risk 
among a single-center cohort of 1178 warfarin-treated patients with 
VTE who did or did not receive bridging LMWH.3 This study also 





Anticoagulation (n = 781) P Value
Mean age (SD) 64.0 (13.9) 61.4 (13.8) 66.5 (13.5) <.001
Male 754 (49.3%) 348 (46.5%) 406 (52.0%) .033
Race
White 1162 (76.0%) 563 (75.3%) 599 (76.7%) .597
Black 247 (16.2%) 128 (17.1%) 119 (15.2%)
Other 120 (7.8%) 57 (7.6%) 63 (8.1%)
Heart failure 151 (9.9%) 50 (6.7%) 101 (12.9%) <.001
Hypertension 1020 (66.7%) 451 (60.3%) 569 (72.9%) <.001
Diabetes 398 (26.0%) 155 (20.7%) 243 (31.1%) <.001
Prior stroke/TIA 164 (10.7%) 64 (8.6%) 100 (12.8%) .007
Prior myocardial 
infarction
108 (7.1%) 34 (4.6%) 74 (9.5%) <.001
Peripheral artery 
disease
148 (9.7%) 45 (6.0%) 103 (13.2%) <.001
Recurrent VTE 629 (41.1%) 332 (44.4%) 297 (38.0%) .012
Provoked VTE 264 (26.1%) 91 (19.5%) 173 (31.7%) <.001
Known 
thrombophilia




14 (0.9%) 12 (1.6%) 2 (0.3%) .006
Cancer 556 (36.4%) 230 (30.8%) 326 (41.7%) <.001
Chronic kidney 
disease
278 (18.2%) 93 (12.4%) 185 (23.7%) <0.001
Chronic liver 
disease
71 (4.6%) 29 (3.9%) 42 (5.4%) .163
Prior bleeding 1010 (66.1%) 477 (63.8%) 533 (68.3%) .065
Heavy alcohol use 120 (7.9%) 50 (6.7%) 70 (9.0%) .098
Antiplatelet 
medications
505 (33.0%) 235 (31.4%) 270 (34.6%) .190
NSAID 
medications
140 (9.2%) 87 (11.6%) 53 (6.8%) .001
Mean HAS-BLED 
(SD)
3.1 (1.5) 2.9 (1.5) 3.4 (1.5) <.001
Mean days on 
warfarin (SD)
997 (1302) 971 (1245) 1022 (1353) .443
<90 d 158 (10.3%) 88 (11.8%) 70 (9.0%) .176
90-364 d 420 (27.5%) 198 (26.5%) 222 (28.4%)
≥365 d 951 (62.2%) 462 (61.8%) 489 (62.6%)
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation; TIA, transient 
ischemic attack.
TA B L E  1   Demographics and 
comorbidities of warfarin-treated patients 
undergoing surgical procedures
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demonstrated a significant increase in the rate of clinically relevant 
bleeding (2.7% vs 0.2%, P = .01) with bridging anticoagulation use. 
Of note, the vast majority of patients in this analysis was considered 
low risk for VTE recurrence. However, this study analyzed patients 
managed largely before the 2012 ACCP guidelines were published. 
Similar results were seen in a nationwide analysis by Sjögren and 
colleagues from Sweeden.4 Examining patients managed between 
2006 and 2011, they found higher rates of bleeding among those 
treated with VTE receiving bridging anticoagulation compared with 
those without any bridging anticoagulation (10.4% vs 2.1%). They 
also reported higher rates of thrombotic complications among the 
patients receiving bridging anticoagulation (10.3% vs 5.3%). Rates of 
bleeding and thromboembolism in this cohort were similar to those 
reported by Clark and colleagues.
A recent meta-analysis of observational studies confirmed the 
increased rate of bleeding without a reduction in thromboembolism 
events for patients with VTE who received periprocedural bridg-
ing LMWH compared with those who did not.9 However, that me-
ta-analysis was limited in its ability to distinguish between patients 
at high and low risk of thromboembolism. Nearly all studies in that 
meta-analysis included patients enrolled before the 2012 ACCP 
guidelines were published.
Potential underuse of bridging anticoagulation is also a concern 
among high-risk patients. Although none of the studies noted previ-
ously had significant numbers of high-risk patients, the meta-analy-
sis demonstrated very low incidence rates of recurrent VTE both in 
the overall analysis and in the subgroup of patients at high thrombo-
embolic risk.9 A randomized trial of bridging is probably warranted 
in high-risk populations, including those with recent VTE and/or 
higher risk thrombophilia. Further research is also needed to address 
optimal periprocedural management of direct oral anticoagulants in 
patients with VTE. The recently published PAUSE trial enrolled only 
patients with atrial fibrillation, limiting its ability to inform peripro-
cedural management for patients with VTE treated with direct oral 
anticoagulant medications.10
Our study enrolled a cohort of patients, most of which had been 
taking warfarin for >12 months since their VTE event. Therefore, our 
ability to completely explore for potential bridging anticoagulation 
practice changes among patients with higher VTE recurrence risk 
(those with <3 months of warfarin therapy or with high-risk throm-
bophilia) was somewhat limited.
Deciding on appropriate use of bridging anticoagulation remains 
a challenge for patients with other thrombotic cardiac conditions, in-
cluding atrial fibrillation and mechanical heart valves. We previously 
have shown significant reductions in the use of bridging anticoag-
ulation for patients with atrial fibrillation following the publication 
of the BRIDGE trial in 2015.11,12 Of note, the overall use of bridging 
anticoagulation among patients with atrial fibrillation was similar 
between the Michigan collaborative and nation-wide data analyses 
(13.6% and 13.0% in November 2017).
Our study has a number of important strengths, including the 
use of manually abstracted clinical data from multiple, diverse clin-
ical sites. We also include the most contemporary data on bridg-
ing anticoagulation use among warfarin-treated VTE patients. 
However, we acknowledge several limitations. First, although our 
data represent six diverse health systems, these health systems 
are located in one geographic area and may not be generalizable to 
other populations or locations. As such, we are subject to potential 
selection bias, given that these patients were all managed by antico-
agulation clinics. And despite their diverse settings, some predomi-
nately manage cardiology patients whereas others manage patients 









134 (47.9%) 146 (52.1%)
Moderate risk 
(n = 1078)
515 (47.8%) 563 (52.2%)
High risk 
(n = 171)
99 (57.9%) 72 (42.1%)
30-day outcomes
Any bleeding 22 (2.9%) 22 (2.8%)
Major bleeding 5 (0.7%) 7 (0.9%)
Stroke 1 (0.1%) 1 (0.1%)




28 (3.7%) 25 (3.2%)
Note: Use of bridging anticoagulation and associated 30-day adverse 
event rates by the American College of Chest Physicians 2012 guideline 
VTE recurrence risk category. Percentages represent rows for VTE risk 
category and columns for 30-day outcomes. Major bleeding defined by 
the International Society on Thrombosis and Haemostasis.7
Abbreviation: VTE, venous thromboembolism.
F I G U R E  1   Guideline-congruent bridging anticoagulation use 
in low- and high-risk patients with VTE. Yearly use of guideline-
congruent bridging anticoagulation, defined as use among patients 
at high risk for VTE recurrence and no use among patients at low 
risk for VTE recurrence according to 2012 American College of 
Chest Physicians8
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with a wide variety of indications for anticoagulation. Second, as 
with any observational study, we are unable to adjust for any un-
measured confounders. Third, our data did not collect procedural 
details until 2016. Therefore, we are unable to report on the types 
of procedures for all patients. However, data from 2016 through 
2018 (Appendix S1) demonstrate a wide range of procedure types. 
Fourth, although bridging anticoagulation was defined in our data 
collection form as therapeutic doses of parenteral anticoagulants, 
further details about the specific medication, dose, or administra-
tion was not collected. Therefore, we cannot comment on differ-
ences in pre- vs postprocedure use of bridging anticoagulation. 
Finally, because use of bridging anticoagulation is determined by in-
dividual clinicians and not standardized across each health system, 
we are unable to associate any center-level differences to specific 
protocols or practices.
In summary, we demonstrate frequent use of bridging anticoag-
ulation among patients with VTE that is not congruent with ACCP 
guideline recommendations. Specifically, overuse of bridging anti-
coagulation remains common for low-risk patients, whereas many 
high-risk patients do not receive bridging anticoagulation during a 
temporary warfarin interruption. Efforts to align bridging antico-
agulation use with guideline- and evidence-based strategies are 
needed.
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